The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 554-561

  Johnson, Skyler ^a   Jackson, William ^a   Li, Darren ^a   Song, Yeohan ^a   Foster, Corey ^a   Foster, Ben ^a   Zhou, Jessica ^a   Vainshtein, Jeffrey ^a   Feng, Felix ^a   Hamstra, Daniel ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; HAZARDS; PATHOLOGY; PATIENT MONITORING; PATIENT TREATMENT; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; COX PROPORTIONAL HAZARDS MODELS; INDEPENDENT PREDICTORS; INTER QUARTILE RANGES; METHODS AND MATERIALS; RADICAL PROSTATECTOMY; RETROSPECTIVE ANALYSIS; SALVAGE RADIATION THERAPIES;

RADIOTHERAPY;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER MORTALITY; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; FOLLOW UP; HUMAN; INTERVAL TO BIOCHEMICAL FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; ANALYSIS OF VARIANCE; BLOOD; CAUSE OF DEATH; COMPUTER ASSISTED RADIOTHERAPY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TIME; TREATMENT FAILURE;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE;

MLCS; MLOWN;

EID: 84880579196     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.016     Document Type: Article

References (21)

1. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-1507.
2. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-2769.
3. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291:1325-1332.
4. Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: The impact of time from surgery to recurrence. Eur Urol 2011;59:893-899.
5. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-2041.
6. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039-5046.
7. Katz MS, Zelefsky MJ, Ventkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-489.
8. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005-7012.
9. Alcantara P, Hanlon A, Buyyounouski MK, et al. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 2007;109:41-47.
10. Buyyounouski MK, Hanlon AL, Horwitz EM, et al. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:59-66.
11. Pollack A, Hanlon AL, Movsas B, et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:19-23.
12. Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005;23:826-831.
13. Buyyounouski MK, Pickles T, Kestin LL, et al. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012;30:1857-1863.
14. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-439.
15. Kapadia NS, Olson K, Sandler HM, et al. Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer 2012;118:2059-2068.
16. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177: 540-545.
17. Harrell FE Jr., Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982;247:2543-2546.
18. Denham JW, Steigler A, Kumar M, et al. Measuring time to biochemical failure in the TROG 96.01 trial: When should the clock start ticking' Int J Radiat Oncol Biol Phys 2009;75:1008-1012.
19. Denham JW, Steigler A, Wilcox C, et al. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival' Cancer 2009;115:4477-4487.
20. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
21. Denham JW, Steigler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 2008;9:1058-1068.